Latest Luoxis Diagnostics Inc. Stories
Eurobio, Una Health Limited, and THP Medical to Introduce RedoxSYS to Prominent Academic and Pharma-Based Research Centers ENGLEWOOD, Colo., Jan.
ENGLEWOOD, Colo., Jan. 6, 2015 /PRNewswire/ -- Luoxis Diagnostics, Inc., a subsidiary of Ampio Pharmaceuticals, Inc.
RedoxSYS Diagnostic System Utilized in Studies of Parkinson's Disease, Multiple Sclerosis, and Exercise-Induced Oxidative Stress in Athletes ENGLEWOOD, Colo., Nov.
ENGLEWOOD, Colo., Oct. 20, 2014 /PRNewswire/ -- Luoxis Diagnostics, Inc., a subsidiary of Ampio Pharmaceuticals, Inc.
Company's research partner, Trauma Research, LLC will present key clinical validation data from a prospective trial utilizing the RedoxSYS(TM) Diagnostic System and oxidation-reduction potential (ORP)
With CE mark in place and FDA-directed studies underway in US, company accelerates market development efforts in US, Canada, Israel, and multiple countries in Europe ENGLEWOOD, Colo.,
Regulatory Clearance Enables Commercialization in Europe and other Key Markets GREENWOOD VILLAGE, Colo., April 2, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc., (NYSE MKT: AMPE)
- The parings of haberdine; also, any kind of fragments.